[ad_1]
(MedPage Today) — An investigational antibody-drug conjugate proved active and safe for patients with previously treated HER2-mutant non-small cell lung cancer (NSCLC), a phase II trial from China showed.
Of 94 patients with locally advanced…
[ad_2]
Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/114398
Author :
Publish date : 2025-02-26 22:44:22
Copyright for syndicated content belongs to the linked Source.
Novel Drug Shrinks 73% of HER2-Mutant Lung Cancers
Related Posts
